Key facts
- This page summarizes Doug Samuelson's Form 4 filing for Kairos Pharma, LTD. (KAPA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Nov 2024, 06:03.
Doug Samuelson - 22 Nov 2024 Form 4 Insider Report for Kairos Pharma, LTD. (KAPA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- KAPA
- Reported as of
- 22 Nov 2024
- Net transaction value
- +$3,750
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2024, 06:03:39 UTC
- Prior SEC filing
- 24 Sep 2024
- Next SEC filing
- 26 Nov 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Doug Samuelson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Doug Samuelson filed Form 4 for Kairos Pharma, LTD. (KAPA) on 25 Nov 2024.
Change
- Previous filing in this sequence was filed on 24 Sep 2024.
- Current net transaction value: +$3,750.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KAPA
transaction
COMMON STOCK
Purchase
- Transaction value
- $3,750
- Shares
- +2,500
- Change %
- +4.3%
- Price
- $1.50
- Shares after
- 60,796
- Date
- 22 Nov 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.